Ovid Therapeutics Inc. (OVID) EPS Estimated At $-0.42

January 20, 2018 - By reb123z

 Ovid Therapeutics Inc. (OVID) EPS Estimated At $ 0.42

Analysts expect Ovid Therapeutics Inc. (NASDAQ:OVID) to report $-0.42 EPS on February, 8.After having $-0.38 EPS previously, Ovid Therapeutics Inc.’s analysts see 10.53 % EPS growth. The stock increased 3.15% or $0.28 during the last trading session, reaching $9.18. About 93,201 shares traded or 38.41% up from the average. Ovid Therapeutics Inc. (NASDAQ:OVID) has 0.00% since January 20, 2017 and is . It has underperformed by 16.70% the S&P500.

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company has market cap of $225.86 million. The firm is developing OV101, a drug candidate that is in Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome, as well as in preclinical development stage for pediatrics with angelman syndrome. It currently has negative earnings. It is also developing OV935, a drug candidate that is in Phase I trial for rare epileptic encephalopathies; preclinical-stage compounds for rare epilepsy disorders; and OV102, an intravenous formulation for indications in the hospital setting.

More notable recent Ovid Therapeutics Inc. (NASDAQ:OVID) news were published by: Globenewswire.com which released: “Ovid Therapeutics Reports Second Quarter 2017 Financial Results and Corporate …” on August 10, 2017, also Seekingalpha.com with their article: “Ovid Therapeutics Continues Streak Of BioPharm Companies Going Public” published on May 03, 2017, Globenewswire.com published: “Ovid Therapeutics Announces Pricing of Initial Public Offering” on May 04, 2017. More interesting news about Ovid Therapeutics Inc. (NASDAQ:OVID) were released by: Seekingalpha.com and their article: “Ovid Therapeutics: Is There More Upside After A 75% Gain In 3 Weeks?” published on November 23, 2017 as well as Seekingalpha.com‘s news article titled: “Ovid Therapeutics: Takeda Partnership And Near Term Catalysts Make This A Buy” with publication date: October 30, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.